Compare Aurora Cannabis Inc (ACB) vs Lucid Group Inc (LCID) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Lucid Group (LCID) trades at $7.04, up 0.86% with a neutral technical signal despite recent earnings misses. The company reported Q2 2026 revenue of $405.3 million (beating estimates) but a wider loss of $3.30 per share due to inventory charges. Management is executing a $1.4 billion operational reset focusing on cost reductions, robotaxi partnerships, and delaying the Cosmos EV launch to 2027. Financial metrics show severe challenges with negative gross margins of -96.56% and net income margin of -249.21%.

The outlook remains high-risk with persistent cash burn and competitive pressures, though analyst consensus targets $10.50 representing 49% upside. Key risks include execution of the turnaround plan, EV market demand, and the need for future capital raises. The stock offers speculative potential if cost savings materialize but faces significant fundamental headwinds.